Prevalence by therapy line and incidence of breast cancer brain metastases in 18 075 patients
JNCI: Journal of the National Cancer Institute · 01.08.2025 · 117 (8) · 1565-1572
DOI: 10.1093/jnci/djaf048 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 31.03.2025. Verfasst von Sarah L Sammons und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States. Hauptthemen laut MEDLINE: Brain Neoplasms, Breast Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: F. Hoffmann-La Roche, AstraZeneca.
Abstract (Originalsprache)
Importance Brain metastases portend poor prognosis in patients with metastatic breast cancer (MBC). Designing treatment and prevention clinical trials requires knowledge of brain metastases incidence with each line of therapy.
Objectives
We assessed the prevalence and cumulative incidence of brain metastases in a large MBC patient cohort by subtype and line of therapy, and the impact of HER2-low expression on prevalence. Design, Setting and Outcomes We analyzed brain metastases prevalence in patients with MBC in a nationwide electronic health record-derived de-identified database. The primary outcome was first diagnosis of brain metastases. We estimated prevalence and incidence of brain metastases by MBC subtype, including HER2-low and therapy line. We used the cumulative incidence function to estimate brain metastases risk in patients without brain metastases at initiation of systemic therapy. All P-values are 2-sided, and a P-value ≤.05 indicates statistical significance.
Results
Among 18 075 patients with MBC, 1102 (6.1%) had at least 1 brain metastasis at first-line therapy initiation. For the remaining 16 973 patients, cumulative incidence of brain metastases at 60 months was 10% in patients with hormone receptor-positive (HR+)/HER2− disease, 23% for HR+/HER2+ disease, 34% for HR−/HER2+ disease, and 22% for triple-negative breast cancer (TNBC). HER2-low expression within HR+/HER2− and TNBC subtypes had no impact on brain metastases incidence. Brain metastases prevalence increased per line of therapy for patients with all breast cancer subtypes.
Conclusions
Brain metastases incidence increases per line of therapy for every MBC subtype. The HER2-low biomarker does not impact brain metastases incidence within historical subtypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
- Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, United States.
- Harvard Medical School, Boston, MA, United States.
- F. Hoffman-La Roche Ltd, Basel, Basel-Stadt, Switzerland.
- Genentech, Inc, South San Francisco, CA, United States.
ORCID-Profile: Sarah L Sammons, Thibaut Sanglier, Jose Pablo Leone, Filippo Montemurro, Raf Poppe, Eleonora Restuccia, Sara M Tolaney, Nancy U Lin
Förderung
- F. Hoffmann-La Roche
- AstraZeneca
Zitieren
APA
Sammons, S. L., Sanglier, T., Leone, J. P., Erick, T. K., Lambert, P., Montemurro, F., Poppe, R., Restuccia, E., Tolaney, S. M., & Lin, N. U. (2025). Prevalence by therapy line and incidence of breast cancer brain metastases in 18 075 patients. JNCI: Journal of the National Cancer Institute, 117(8), 1565-1572. https://doi.org/10.1093/jnci/djaf048
Vancouver
Sammons SL, Sanglier T, Leone JP, Erick TK, Lambert P, Montemurro F, et al. Prevalence by therapy line and incidence of breast cancer brain metastases in 18 075 patients. JNCI: Journal of the National Cancer Institute. 2025;117(8):1565-1572. doi:10.1093/jnci/djaf048
BibTeX
@article{Sammons2025,
author = {Sammons, Sarah L and Sanglier, Thibaut and Leone, Jose Pablo and Erick, Timothy K and Lambert, Peter and Montemurro, Filippo and Poppe, Raf and Restuccia, Eleonora and Tolaney, Sara M and Lin, Nancy U},
title = {Prevalence by therapy line and incidence of breast cancer brain metastases in 18 075 patients},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
volume = {117},
number = {8},
pages = {1565--1572},
doi = {10.1093/jnci/djaf048}
}
EUVIMED